ASCO 2026 Deep Dive: InnoCare’s New BCL2 Inhibitor Dropped Game-Changing Blood Cancer Data

(SeaPRwire) –

I caught up with David Carter, a 20-year veteran oncology biotech R&D advisor who’s been covering ASCO for over a decade, to get his first take on the new data. “I’ve followed BCL2 inhibitor development for 20 years, and this data from InnoCare stopped me cold when it hit the conference floor. The biggest unmet need in first-line AML and MDS right now, especially for TP53 mutant patients, is a regimen that works fast, is tolerable, and delivers deep, durable remission. Existing approved BCL2 inhibitors still struggle with resistance and underwhelming response rates in high-risk subsets. To hit these response numbers is not just an incremental improvement—it’s a milestone that could redefine standard of care if results hold.”

I dug through the full dataset released at the meeting to pull out all the core numbers that matter. InnoCare is a commercial-stage biotech focused on cancer and autoimmune diseases, dual-listed on the Hong Kong Stock Exchange and Shanghai Stock Exchange (HKEX: 09969; SSE: 688428). The data shared at ASCO this year is for the company’s novel BCL2 inhibitor mesutoclax, tested in combination with azacitidine for treatment-naive myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and the work was featured as an official oral presentation.

As of the April 20, 2026 data cutoff for MDS patients, all evaluable treatment-naive patients hit a 100% overall response rate per the 2006 International Working Group (IWG) response criteria for myelodysplasia. That breaks down to a 40% complete response rate and 60% marrow complete response rate. Per the updated 2023 IWG criteria, the composite complete response rate hits 90%, with 60% of patients achieving full complete response.

For the AML cohort, the data cutoff was April 13, 2026. 81.8% of evaluable treatment-naive patients achieved composite complete response (cCR, defined as CR plus complete response with incomplete hematologic recovery, or CRi), and 86.5% of all patients tested negative for minimal residual disease. 83% of cCR responders achieved remission in their first treatment cycle, confirming the regimen delivers rapid, deep remissions. In the 125mg mesutoclax dose group, the 6-month duration of response rate was 93.3% and the 6-month overall survival rate was 90.5%. Even in the hard-to-treat subgroup of treatment-naive AML patients with TP53 mutations, the cCR rate reached 71.4% and the 6-month duration of response rate exceeded 50%.

On safety, no dose-limiting toxicities were observed, and the maximum tolerated dose was not reached. Most non-hematologic adverse events were grade 1 or 2. The robust efficacy of the combination allowed patients to recover from cytopenia quickly, and 30-day and 60-day mortality for treatment-naive AML patients both stood at 0%. To date, InnoCare has brought three drugs to market, holds more than ten additional innovative drug candidates in clinical development, and runs multiple preclinical programs, with operations across China and the United States.

Looking beyond this single trial, this result signals a bigger shift in the global oncology landscape. BCL2 inhibition has long been a core target for blood cancer, but current generation drugs still struggle to deliver consistent results in high-risk genetic subsets like TP53-mutant AML. Novel BCL2 inhibitor combinations are one of the most active areas of clinical development globally, as teams race to overcome existing resistance limitations.

This data from InnoCare makes clear that Chinese innovative biotech is no longer just following in the footsteps of global players. It’s now delivering best-in-class data that competes head-to-head with the top programs at the industry’s most prestigious conference. If mesutoclax can replicate these early results in larger phase 3 trials, it will likely become a new preferred first-line option for MDS and AML, filling a critical gap for high-risk patients who currently have few effective options. We’ll likely see more Chinese-developed innovative oncology drugs take center stage at global conferences in the coming years, reshaping how patients around the world access cutting-edge treatment.